Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 13/20 | 0.79 |
| ▸ | FLT4 | P35916 | 13/20 | 0.79 |
| ▸ | KDR | P35968 | 13/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10989349 | 0.89 | FLT1 (1.00) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL9185479 | 0.85 | FLT1 (0.55) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL7213397 | 0.85 | PTGS2 (0.64) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL16634417 | 0.84 | FLT1 (0.67) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL7319450 | 0.84 | FLT1 (0.58) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL9014174 | 0.83 | FLT1 (0.87) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL7287948 | 0.83 | FLT1 (0.87) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL24224258 | 0.81 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL9176789 | 0.81 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL789891 | 0.81 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0362002-B1 | HIV protease inhibitors | MERRELL DOW PHARMA (US) | 1995-07-26 | — | — | EP | claimed |
| US-6617426-B1 | Peptide analogs of given formula; useful in treating neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury | MERCK SHARP & DOHME CORP. | 2003-09-09 | — | — | US | disclosed |
| EP-1194443-A1 | CYSTEINYL PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6172044-B1 | ELASTASE INHIBITORS; ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000078794-A1 | CYSTEINYL PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6153171-A | Methods for identifying compounds effective for treating neurodegenerative disorders and for monitoring the therapeutic intervention therefor | SIBIA NEUROSCIENCES, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0707564-B1 | DIFLUORO STATONE ANALOGS | MERRELL PHARMA INC (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6114380-A | ANTIVIRAL AGENT; ADMINISTERING TO TREAT HIV INFECTION; N-(4-(N-BENZYLOXYCARBONYL-L-VALYL)AMINO-2,2-DIFLUORO-1,3-DIOXO-5-(4-(2-N -MORPHOLYL)ETHYLOXY)PHENYL-PENTYL)-O-((2-PYRIDYL)METHYL)-D-VALINOL, FOR EXAMPLE | MERRELL PHARMACEUTICALS INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6051684-A | CONTACTING A COMPOSITION CONTAINING AMYLOID PRECURSOR PROTEIN WITH DI- OR TRIPEPTIDE ANALOG CAUSING A DECREASE IN A-BETA-PEPTIDE OR AN INCREASE IN ALPHA-S-AMYLOID PRECURSOR PROTEIN | SIBIA NEUROSCIENCES INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0589937-B1 | USE OF 4-(4-CHLOROPHENYL-SULPHONYLCARBAMOYL) BENZOYL-L-VALYL-L-PROLINE 1(RS)-(1-TRIFLUOROACETYL-2-METHYLPROPYL) AMIDE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF VASCULAR DISEASES | ZENECA LTD (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0417721-A2 | Novel peptidase and isomerase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0410411-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0371179-A1 | Novel analogs of peptidase substrates | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| EP-0368719-A2 | Novel analogs of peptidase substrates | MERRELL PHARMACEUTICALS INC. (US) | 1990-05-16 | — | — | EP | disclosed |
| CN-1041951-A | New peptidase inhibitors | MERRELL DOW PHARMA (US) | 1990-05-09 | — | — | CN | disclosed |
| EP-0364344-A2 | Novel peptidase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-18 | — | — | EP | disclosed |
| EP-0363284-A2 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| CN-86101066-A | Process for producing novel trifluoromethyl ketone substituted peptide derivatives | — | 1986-11-05 | — | — | CN | disclosed |